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Harpaz [1] argues that what has, and has not, taken place in the US, even if it does not quite 
yet allow theoretical concerns about reduced exogenous boosting following universal 
varicella vaccine introduction to be completely ignored, ought at the very least to provoke 
some revision of the models being used to estimate the timing, size and duration of any 
such rise. After all, at some point real life must surely trump prophecy? Van Hoek chooses 
instead to continue to argue that exogenous boosting may actually matter and proposes 
that it may help explain rises in zoster occurring both in the absence of vaccination and 
following it – although he does not offer an explanation as to why, in that case, notional 
vaccine-induced effects replaced the effects occurring prior to vaccination but did not 
augment them, nor why more recent US data suggest that the rise, far from accelerating, 
appears to have stopped at the very time the models would have had them taking off. 
 
But, perhaps because the scope of the paper does not extend beyond Hope-Simpson’s 
exogenous hypothesis, neither author points out that it invokes a theoretical problem to 
which we already have a solution. Live attenuated zoster vaccine, while effective [2], may 
provide only temporary and partial protection and cannot be used in some elderly people 
who are at the highest risk. But available evidence suggests strongly that the recently-
licensed non-live adjuvanted vaccine overcomes these limitations [3]. Surely it is time for 
policy makers to stop imagining that they have to continue to permit much preventable 
morbidity to occur in children in order to protect adults from zoster, when they can use 
zoster vaccine to do the job instead? 
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